BACKGROUND AND PURPOSE: Prostaglandin (PG) D(2) has emerged as a key mediator of allergic inflammatory pathologies and, particularly, PGD(2) induces leukotriene (LT) C(4) secretion from eosinophils. Here, we have characterized how PGD(2) signals to induce LTC(4) synthesis in eosinophils. EXPERIMENTAL APPROACH: Antagonists and agonists of DP(1) and DP(2) prostanoid receptors were used in a model of PGD(2) -induced eosinophilic inflammation in vivo and with PGD(2) -stimulated human eosinophils in vitro, to identify PGD(2) receptor(s) mediating LTC(4) secretion. The signalling pathways involved were also investigated. KEY RESULTS: In vivo and in vitro assays with receptor antagonists showed that PGD(2) -triggered cysteinyl-LT (cysLT) secretion depends on the activation of both DP(1) and DP(2) receptors. DP(1) and DP(2) receptor agonists elicited cysLTs production only after simultaneous activation of both receptors. In eosinophils, LTC(4) synthesis, but not LTC(4) transport/export, was activated by PGD(2) receptor stimulation, and lipid bodies (lipid droplets) were the intracellular compartments of DP(1) /DP(2) receptor-driven LTC(4) synthesis. Although not sufficient to trigger LTC(4) synthesis by itself, DP(1) receptor activation, signalling through protein kinase A, did activate the biogenesis of eosinophil lipid bodies, a process crucial for PGD(2) -induced LTC(4) synthesis. Similarly, concurrent DP(2) receptor activation used Pertussis toxin-sensitive and calcium-dependent signalling pathways to achieve effective PGD(2) -induced LTC(4) synthesis. CONCLUSIONS AND IMPLICATIONS: Based on pivotal roles of cysLTs in allergic inflammatory pathogenesis and the collaborative interaction between PGD(2) receptors described here, our data suggest that both DP(1) and DP(2) receptor antagonists might be attractive candidates for anti-allergic therapies.
BACKGROUND AND PURPOSE:Prostaglandin (PG) D(2) has emerged as a key mediator of allergic inflammatory pathologies and, particularly, PGD(2) induces leukotriene (LT) C(4) secretion from eosinophils. Here, we have characterized how PGD(2) signals to induce LTC(4) synthesis in eosinophils. EXPERIMENTAL APPROACH: Antagonists and agonists of DP(1) and DP(2) prostanoid receptors were used in a model of PGD(2) -induced eosinophilic inflammation in vivo and with PGD(2) -stimulated human eosinophils in vitro, to identify PGD(2) receptor(s) mediating LTC(4) secretion. The signalling pathways involved were also investigated. KEY RESULTS: In vivo and in vitro assays with receptor antagonists showed that PGD(2) -triggered cysteinyl-LT (cysLT) secretion depends on the activation of both DP(1) and DP(2) receptors. DP(1) and DP(2) receptor agonists elicited cysLTs production only after simultaneous activation of both receptors. In eosinophils, LTC(4) synthesis, but not LTC(4) transport/export, was activated by PGD(2) receptor stimulation, and lipid bodies (lipid droplets) were the intracellular compartments of DP(1) /DP(2) receptor-driven LTC(4) synthesis. Although not sufficient to trigger LTC(4) synthesis by itself, DP(1) receptor activation, signalling through protein kinase A, did activate the biogenesis of eosinophil lipid bodies, a process crucial for PGD(2) -induced LTC(4) synthesis. Similarly, concurrent DP(2) receptor activation used Pertussis toxin-sensitive and calcium-dependent signalling pathways to achieve effective PGD(2) -induced LTC(4) synthesis. CONCLUSIONS AND IMPLICATIONS: Based on pivotal roles of cysLTs in allergic inflammatory pathogenesis and the collaborative interaction between PGD(2) receptors described here, our data suggest that both DP(1) and DP(2) receptor antagonists might be attractive candidates for anti-allergic therapies.
Authors: Nicole Sawyer; Elizabeth Cauchon; Anne Chateauneuf; Rani P G Cruz; Donald W Nicholson; Kathleen M Metters; Gary P O'Neill; Francois G Gervais Journal: Br J Pharmacol Date: 2002-12 Impact factor: 8.739
Authors: Adriana Vieira-de-Abreu; Edson F Assis; Gleice S Gomes; Hugo C Castro-Faria-Neto; Peter F Weller; Christianne Bandeira-Melo; Patrícia T Bozza Journal: Am J Respir Cell Mol Biol Date: 2005-06-09 Impact factor: 6.914
Authors: Christianne Bandeira-Melo; Kumiya Sugiyama; Lesley J Woods; Mojabeng Phoofolo; David M Center; William W Cruikshank; Peter F Weller Journal: J Immunol Date: 2002-05-01 Impact factor: 5.422
Authors: Nicodemus Tedla; Christianne Bandeira-Melo; Paolo Tassinari; David E Sloane; Mary Samplaski; David Cosman; Luis Borges; Peter F Weller; Jonathan P Arm Journal: Proc Natl Acad Sci U S A Date: 2003-01-14 Impact factor: 11.205
Authors: H Hirai; K Tanaka; O Yoshie; K Ogawa; K Kenmotsu; Y Takamori; M Ichimasa; K Sugamura; M Nakamura; S Takano; K Nagata Journal: J Exp Med Date: 2001-01-15 Impact factor: 14.307
Authors: James P Hardwick; Katie Eckman; Yoon Kwang Lee; Mohamed A Abdelmegeed; Andrew Esterle; William M Chilian; John Y Chiang; Byoung-Joon Song Journal: Adv Pharmacol Date: 2013
Authors: Tatiana Luna-Gomes; Kelly G Magalhães; Fabio P Mesquita-Santos; Ilka Bakker-Abreu; Rafaela F Samico; Raphael Molinaro; Andrea S Calheiros; Bruno L Diaz; Patrícia T Bozza; Peter F Weller; Christianne Bandeira-Melo Journal: J Immunol Date: 2011-11-18 Impact factor: 5.422
Authors: Tae Chul Moon; Eduardo Campos-Alberto; Tsuyoshi Yoshimura; Graeme Bredo; Aja M Rieger; Lakshmi Puttagunta; Daniel R Barreda; A Dean Befus; Lisa Cameron Journal: PLoS One Date: 2014-09-30 Impact factor: 3.240
Authors: Natália R T Amorim; Tatiana Luna-Gomes; Marcos Gama-Almeida; Glaucia Souza-Almeida; Claudio Canetti; Bruno L Diaz; Peter F Weller; Patricia Torres Bozza; Clarissa M Maya-Monteiro; Christianne Bandeira-Melo Journal: Front Immunol Date: 2018-09-20 Impact factor: 7.561